Didier Noël Carlotti
Research Subjects
Research Interests
Didier Noël Carlotti has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
C. Dauvert
Service de dermatologie, clinique vétérinaire Aquivet, parc d’activités J.-Mermoz, rue de la Forêt, 33320 Eysines, Bordeaux, France
1 shared publicationC. Laffort-Dassot
Clinique vétérinaire alliance, 8, boulevard Godard, 33300 Bordeaux, France
1 shared publicationC. Malet
Service de chirurgie, clinique vétérinaire Aquivet, parc d’activités J.-Mermoz, rue de la Forêt, 33320 Eysines, France
1 shared publicationChristophe A. Rème
Virbac SA, 13e Rue, BP 27, F‐06515 Carros, France
1 shared publicationDennis E. Jacobs
Department of Pathology and Infectious Diseases, The Royal Veterinary College (University of London), North Mymms, Hatfield, Herts AL9 7TA, United Kingdom
1 shared publicationEtienne Meissonnier
Janssen Santé Animale, 1 rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux, France
1 shared publication
Latest Publications
- 1 October 2009
- Published by Wiley in Veterinary Dermatology
- Vol. 20 (5-6) , 405-411
The use of recombinant omega interferon therapy in canine atopic dermatitis: a double‐blind controlled study
This double‐blind controlled study assessed whether reduced doses of omega interferon (rFeIFN‐ω) (Virbagen®Omega) could improve the clinical signs of canine atopic dermatitis (CAD) over a 6‐month period, in comparison with cyclosporin. Thirty‐one dogs diagnosed with CAD were entered in the study. Complicating infections were treated prior to entry. Dogs received 10 injections of rFeIFN‐ω (1–5 million units according to bodyweight) or placebo over 6 months, and placebo capsules or cyclosporin (5 mg/kg) once daily for 2 months and then twice weekly for 4 months in groups 1 and 2 respectively. Flea control, non‐medicated shampooing and ear cleansing were performed regularly. If a bacterial infection orMalasseziaovergrowth developed, it was treated with oral cephalexin or with 3% chlorhexidine shampoo respectively. Oral prednisolone was used before day 90 to relieve pruritus when required for humane reasons (1 mg/kg once daily for 7 days). The CADESI‐03 and a pruritus index were evaluated on day (D) 0, D14, D35, D56, D90, D120 and D180. No significant difference was detected between the groups for the time courses of lesions or pruritus over 6 months. On D90, the proportions of dogs with ≥50% improvement of pruritus and lesion scores were 56% and 72% respectively with interferon, 75% and 75% respectively with cyclosporin. Five dogs from group 1 and two dogs from group 2 were withdrawn from the study for treatment failure. Both products were well tolerated. Treatment with rfeIFN‐ω at low doses may help for the long‐term management of CAD.
- 1 October 2009
- Published by Wiley in Veterinary Dermatology
- Vol. 20 (5-6) , 405-411
The use of recombinant omega interferon therapy in canine atopic dermatitis: a double‐blind controlled study
This double‐blind controlled study assessed whether reduced doses of omega interferon (rFeIFN‐ω) (Virbagen®Omega) could improve the clinical signs of canine atopic dermatitis (CAD) over a 6‐month period, in comparison with cyclosporin. Thirty‐one dogs diagnosed with CAD were entered in the study. Complicating infections were treated prior to entry. Dogs received 10 injections of rFeIFN‐ω (1–5 million units according to bodyweight) or placebo over 6 months, and placebo capsules or cyclosporin (5 mg/kg) once daily for 2 months and then twice weekly for 4 months in groups 1 and 2 respectively. Flea control, non‐medicated shampooing and ear cleansing were performed regularly. If a bacterial infection orMalasseziaovergrowth developed, it was treated with oral cephalexin or with 3% chlorhexidine shampoo respectively. Oral prednisolone was used before day 90 to relieve pruritus when required for humane reasons (1 mg/kg once daily for 7 days). The CADESI‐03 and a pruritus index were evaluated on day (D) 0, D14, D35, D56, D90, D120 and D180. No significant difference was detected between the groups for the time courses of lesions or pruritus over 6 months. On D90, the proportions of dogs with ≥50% improvement of pruritus and lesion scores were 56% and 72% respectively with interferon, 75% and 75% respectively with cyclosporin. Five dogs from group 1 and two dogs from group 2 were withdrawn from the study for treatment failure. Both products were well tolerated. Treatment with rfeIFN‐ω at low doses may help for the long‐term management of CAD.
- 24 August 2009
- Published by Wiley in Veterinary Dermatology
- Vol. 21 (3) , 259-266
Eradication of feline dermatophytosis in a shelter: a field study
Enzootic dermatophytosis in a shelter with approximately 140 cats was treated according to a protocol combining identification, isolation and treatment of subclinical carrier and affected animals in accordance with a three-area system: healthy animals (no lesions and negative cultures), subclinical carrier animals (no lesions but with positive cultures) and clinically affected animals (lesions and positive cultures). The cats were examined and inspected under a Wood’s lamp and had samples taken for fungal culture every 2 weeks. Thirty-three per cent of the cats had a positive fungal culture at the start of the study. Clinically affected animals and carriers were treated with a 0.2% enilconazole lotion (Imaverol®) twice a week and given itraconazole (Itrafungol®) 5 mg/kg SID orally every other week. The environment was treated once a day with a 1% bleach solution and once a week with a 0.6% enilconazole (Clinafarm®) solution. Treated animals were considered cured after two consecutive negative fungal cultures. All cats were cured within 56 days. Prophylactic measures against dermatophytosis were implemented for new arrivals consisting of individual quarantine and the systematic taking of fungal cultures. No relapses were observed based on the fungal cultures taken from the animals and the environment over the first 10 months.
- 24 August 2009
- Published by Wiley in Veterinary Dermatology
- Vol. 21 (3) , 259-266
Eradication of feline dermatophytosis in a shelter: a field study
Enzootic dermatophytosis in a shelter with approximately 140 cats was treated according to a protocol combining identification, isolation and treatment of subclinical carrier and affected animals in accordance with a three-area system: healthy animals (no lesions and negative cultures), subclinical carrier animals (no lesions but with positive cultures) and clinically affected animals (lesions and positive cultures). The cats were examined and inspected under a Wood’s lamp and had samples taken for fungal culture every 2 weeks. Thirty-three per cent of the cats had a positive fungal culture at the start of the study. Clinically affected animals and carriers were treated with a 0.2% enilconazole lotion (Imaverol®) twice a week and given itraconazole (Itrafungol®) 5 mg/kg SID orally every other week. The environment was treated once a day with a 1% bleach solution and once a week with a 0.6% enilconazole (Clinafarm®) solution. Treated animals were considered cured after two consecutive negative fungal cultures. All cats were cured within 56 days. Prophylactic measures against dermatophytosis were implemented for new arrivals consisting of individual quarantine and the systematic taking of fungal cultures. No relapses were observed based on the fungal cultures taken from the animals and the environment over the first 10 months.
- 1 July 2009
- Published by Elsevier in Pratique Médicale et Chirurgicale de l'Animal de Compagnie
- Vol. 44 (3) , 101-107
Un cas de mycobactériose atypique à Mycobacterium fortuitum chez un jeune chat non immunodéprimé
- 1 July 2009
- Published by Elsevier in Pratique Médicale et Chirurgicale de l'Animal de Compagnie
- Vol. 44 (3) , 101-107
Un cas de mycobactériose atypique à Mycobacterium fortuitum chez un jeune chat non immunodéprimé
- 1 January 2008
- Published by Elsevier in Pratique Médicale et Chirurgicale de l'Animal de Compagnie
- Vol. 43 (1) , 1-13
Le traitement des dermatophytoses du chien et du chat. Gestion de la teigne en chatterie
- 1 January 2008
- Published by Elsevier in Pratique Médicale et Chirurgicale de l'Animal de Compagnie
- Vol. 43 (1) , 1-13
Le traitement des dermatophytoses du chien et du chat. Gestion de la teigne en chatterie
- 1 June 2000
- Published by Wiley in Veterinary Dermatology
- Vol. 11 (2) , 83-98
Therapy, control and prevention of flea allergy dermatitis in dogs and cats
This article reviews contemporary concepts underlying the design of control strategies for the management of flea allergy dermatitis in dogs and cats. The limitations of palliative symptomatic approaches are noted, as is the fundamental requirement to differentiate simple pulicosis from true hypersensitivity. In the latter case, eradication of fleas from the affected animal and its surroundings has to be an essential aim. The different biological properties offered by modern chemotherapy are defined and the range of techniques for applying active compounds to the animal and its environment described. Factors for consideration when formulating control strategies and selecting chemotherapeutic agents are discussed in the context of the complexities of the flea life‐cycle, the host‐parasite relationship and client concerns.
- 1 June 2000
- Published by Wiley in Veterinary Dermatology
- Vol. 11 (2) , 83-98
Therapy, control and prevention of flea allergy dermatitis in dogs and cats
This article reviews contemporary concepts underlying the design of control strategies for the management of flea allergy dermatitis in dogs and cats. The limitations of palliative symptomatic approaches are noted, as is the fundamental requirement to differentiate simple pulicosis from true hypersensitivity. In the latter case, eradication of fleas from the affected animal and its surroundings has to be an essential aim. The different biological properties offered by modern chemotherapy are defined and the range of techniques for applying active compounds to the animal and its environment described. Factors for consideration when formulating control strategies and selecting chemotherapeutic agents are discussed in the context of the complexities of the flea life‐cycle, the host‐parasite relationship and client concerns.